[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-portal-vein-tumor-invasion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-portal-vein-tumor-invasion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100514900","tace-plus-atezolizumabbevacizumab-and-i-125-seeds-brachytherapy-for-hcc-with-branch-pvtt-100514900",false,"NCT05984511","TACE Plus Atezolizumab\u002FBevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT","TACE Plus Atezolizumab\u002FBevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT: A Phase III, Randomized Clinical Trial","Inclusion Criteria:\n\n* Age between18 and 75 years;\n* Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n* Type I PVTT or type II PVTT;\n* Child-Pugh class A;\n* Eastern Cooperative Group performance status (ECOG) score of 0-1;\n* No prior systemic therapy for HCC.\n* Adequate hematologic and end-organ function;\n* At least one measurable intrahepatic target lesion.\n\nExclusion Criteria:\n\n* Diffuse HCC;\n* Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible;\n* Evidence of extrahepatic spread (EHS);\n* Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators;\n* Evidence or history of bleeding diathesis or any hemorrhage or bleeding event \\>CTCAE grade 3 within 4 weeks prior to randomization;\n* Active or history of autoimmune disease or immune deficiency;\n* Untreated or incompletely treated esophageal and\u002For gastric varices with bleeding or high risk for bleeding;\n* A prior bleeding event due to esophageal and\u002For gastric varices within 6 months prior to initiation of study treatment;\n* Evidence of bleeding diathesis or significant coagulopathy;\n* Pregnant or breastfeeding females;\n* Significant cardiovascular disease;\n* Severe infection, such as active tuberculosis;\n* Serious medical comorbidities;\n* History of organ or cells transplantation;\n* History of other uncurable malignancies.","ALL","18 Years","75 Years",{"count":20,"type":21},234,"ESTIMATED","INTERVENTIONAL",[24],"NA","The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab\u002FBevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab\u002FBevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I\u002FII PVTT (Based on Cheng's PVTT classification).",[27,28,29],"Hepatocellular Carcinoma","Hepatic Portal Vein Tumor Invasion","Tumor Thrombus",[31,32,33,34,35],"Hepatocellular Carcinoma (HCC)","Portal vein tumor thrombosis (PVTT)","Transcatheter arterial chemoembolization (TACE)","I-125 Seeds Brachytherapy","Atezolizumab plus Bevacizumab","RECRUITING","2025-02-07",{"date":39,"type":40},"2025-02-11","ACTUAL",{"date":42,"type":40},"2023-08-30",{"date":44,"type":21},"2029-08-01",{"name":46,"class":47},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER"]